SEC Form 4 · accession 0001104659-17-060860
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Suzanne Louise Bruhn
Director
Period of report
Oct 2, 2017
Accepted (ET)
Oct 4, 2017 · 4:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $7.16 | Oct 2, 2017 | A | 9,600 | A | — | Oct 2, 2027 | Common Shares | 9,600 | 9,600 | D |
Explanation of responses
- F1Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date.
- F2The common shares underlying this stock option award will vest in equal monthly installments over 36 months, beginning one month after the grant date.